Compare Stocks → The Gold Grab of the Century (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLLSNASDAQ:DBVTNASDAQ:FNCHNASDAQ:MGTXNASDAQ:TALS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.99$2.60$0.96▼$3.77$166.18M3.0852,270 shs90,809 shsDBVTDBV Technologies$0.67$0.76$0.65▼$2.37$128.63M0.7334,837 shs28,964 shsFNCHFinch Therapeutics Group$2.30-7.6%$2.52$1.86▼$16.74$3.70M0.46103,209 shs53,342 shsMGTXMeiraGTx$5.00+0.2%$5.73$3.49▼$8.35$321.55M1.31138,019 shs78,548 shsTALSTalaris Therapeutics$15.84-0.5%$18.84$0.89▼$27.95$677.38M2.18386,531 shs191,659 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%+19.33%+7.17%+1.36%+60.75%DBVTDBV Technologies-1.19%-2.93%-11.73%-26.44%-57.56%FNCHFinch Therapeutics Group-7.63%-0.86%-2.54%-14.34%-79.01%MGTXMeiraGTx+0.20%+4.17%-7.92%-15.40%-14.38%TALSTalaris Therapeutics+1.34%-0.50%-26.97%-54.72%+468.57%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis1.7425 of 5 stars3.52.00.00.00.82.50.6DBVTDBV Technologies3.0604 of 5 stars3.23.00.00.02.63.31.3FNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx3.1495 of 5 stars3.53.00.04.80.01.70.6TALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis3.00Buy$8.50184.28% UpsideDBVTDBV Technologies2.33Hold$5.00649.74% UpsideFNCHFinch Therapeutics GroupN/AN/AN/AN/AMGTXMeiraGTx3.00Buy$25.67413.33% UpsideTALSTalaris TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CLLS, MGTX, TALS, DBVT, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$9.19M18.08N/AN/A$2.76 per share1.08DBVTDBV Technologies$15.73M8.18N/AN/A$0.73 per share0.91FNCHFinch Therapeutics Group$110K33.66N/AN/A$14.25 per share0.16MGTXMeiraGTx$14.02M22.94N/AN/A$2.17 per share2.30TALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$106.14M-$1.72N/AN/AN/A-346.65%-73.03%-32.22%N/ADBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%N/AFNCHFinch Therapeutics Group-$74.75M-$47.67N/A∞N/AN/A-136.63%-57.40%5/8/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.56N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)TALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/ALatest CLLS, MGTX, TALS, DBVT, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2024Q4 2023CLLSCellectisN/A-$0.64-$0.64-$0.64N/A$1.99 million3/25/2024Q4 2023FNCHFinch Therapeutics GroupN/A-$1.89-$1.89-$1.89N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.572.202.20DBVTDBV TechnologiesN/A4.264.26FNCHFinch Therapeutics GroupN/A6.336.33MGTXMeiraGTx0.622.382.38TALSTalaris TherapeuticsN/A15.4115.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%DBVTDBV Technologies71.74%FNCHFinch Therapeutics Group21.77%MGTXMeiraGTx67.48%TALSTalaris Therapeutics67.61%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%DBVTDBV Technologies0.71%FNCHFinch Therapeutics Group44.90%MGTXMeiraGTx9.70%TALSTalaris Therapeutics16.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis23155.58 million46.46 millionOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableFNCHFinch Therapeutics Group11.61 million885,000No DataMGTXMeiraGTx41964.31 million58.07 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableCLLS, MGTX, TALS, DBVT, and FNCH HeadlinesSourceHeadlineCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officerfinanznachrichten.de - April 29 at 8:32 AMLongitude Venture Partners III, L.P.'s Net Worthbenzinga.com - February 25 at 9:31 PMTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15msn.com - November 1 at 8:40 AMTalaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complexdhakatribune.com - October 20 at 7:22 AMTalaris Therapeutics goes ex-dividend tomorrowmsn.com - October 19 at 3:47 PMTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinanznachrichten.de - October 18 at 8:02 AMTalaris shareholders approve merger, 1-for-10 reverse stock splitmsn.com - October 17 at 10:28 PMTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinance.yahoo.com - October 17 at 10:28 PMTalaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling Alertknoxdaily.com - October 16 at 1:01 PMShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Mergermarketwatch.com - October 6 at 8:19 PMTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Biofinance.yahoo.com - October 6 at 8:19 PMNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeuticsfinance.yahoo.com - October 4 at 9:59 AMWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Ratefinance.yahoo.com - September 12 at 5:34 PMSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,bakersfield.com - August 23 at 11:00 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTmarkets.businessinsider.com - August 15 at 6:25 PMImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Businessfinance.yahoo.com - August 14 at 3:38 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFmarkets.businessinsider.com - August 8 at 8:33 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHLbakersfield.com - July 29 at 5:47 PMMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firmbenzinga.com - July 28 at 4:44 PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)markets.businessinsider.com - July 27 at 11:10 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSmarkets.businessinsider.com - July 18 at 1:26 PMTalaris Therapeutics: Cashing Out Ahead Of Tourmaline Mergermsn.com - July 18 at 8:26 AMDirector Ildstad Suzanne sale 12,942 shares of Talaris Therapeutics Inc. [TALS]knoxdaily.com - July 14 at 11:38 PMTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75msn.com - July 6 at 8:45 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesCVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?April 30, 2024 9:25 AMView CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?3 A.I. Stocks to Watch Out For Not Named NVIDIA April 23, 2024 7:00 AMView 3 A.I. Stocks to Watch Out For Not Named NVIDIA 2 Stocks to Benefit From New Sanctions on Russian AluminumApril 23, 2024 6:20 AMView 2 Stocks to Benefit From New Sanctions on Russian AluminumCan Netflix Stock Continue Into All-Time Highs After Earnings?April 18, 2024 7:32 AMView Can Netflix Stock Continue Into All-Time Highs After Earnings?Comprehensive Analysis of PayPal StockApril 19, 2024 11:45 AMView Comprehensive Analysis of PayPal StockAll Headlines Company DescriptionsCellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Finch Therapeutics GroupNASDAQ:FNCHFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.